Loading
institutionsInstitution
Nantes University Hospital (CHU de Nantes)
The university hospital of Nantes, whose haematology department under Philippe Moreau is one of the two French centres that lead the Intergroupe Francophone du Myélome trials.
Also called: Hôtel-Dieu de NantesCHU NantesUniversity Hospital Hôtel-Dieu
Overview
The CHU de Nantes is the university hospital of Nantes in western France; its Hôtel-Dieu site houses the Department of Hematology, led by Philippe Moreau. With Lille, Nantes anchors the Intergroupe Francophone du Myélome, and Moreau was first author of the IKEMA and MAIA-era trials and of the 2022 New England Journal of Medicine report of teclistamab in relapsed myeloma. The Institut de Cancérologie de l'Ouest, the region's dedicated cancer centre, is a separate institution.
Location
Nantes, FR
Type
hospital · Nantes Université
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#615 · 4 points (0 Newsweek + 0 NCI + 4 from 2 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Centre Hospitalier Universitaire de Rennes, including child institutions. 424 works · 3,966 citations · 68% open access · 14% clinical trials · 1% reviews.
Oncology works per year
792022
1032023
872024
862025
692026
Most works
- Roch Houot110 works
- Emmanuel Bachy56 works
- Thomas Gastinne44 works
- Sylvain Choquet42 works
- Catherine Thiéblemont39 works
- Steven Le Gouill38 works
- Guillaume Cartron37 works
- Franck Morschhauser37 works
- Roberta Di Blasi32 works
- Olivier Casasnovas31 works
Most cited
- Multiple myeloma (IFM)
- Haematology
- Bispecific antibody trials
Similar pages
- TrialMajesTEC-3
Shares Philippe Moreau, Multiple myeloma.
- TrialMajesTEC-1
Shares Philippe Moreau, Multiple myeloma.
- TrialCASSIOPEIA
Shares Philippe Moreau, Multiple myeloma.
- Key paperMajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma
Shares Philippe Moreau, Multiple myeloma.
- TreatmentTeclistamab
Shares Philippe Moreau, Multiple myeloma.
- TargetCD38
Shares Philippe Moreau, Multiple myeloma.